1	Rethinking immunologic risk: a retrospective cohort study of severe SARS-CoV-2 infections in		
2	individuals with congenital immunodeficiencies		
3			
4	Alan A. Nguyen*, Saddiq B. Habiballah* [†] , Brenna LaBere*, Megan Day-Lewis, Megan Elkins, Amer Al-		
5	Musa, Anne Chu, Jennifer Jones, Ari J. Fried, Douglas McDonald, David P. Hoytema van Konijnenburg,		
6	Shira Rockowitz, Piotr Sliz, Hans C. Oettgen, Lynda C. Schneider, Andrew MacGinnitie, Lisa M.		
7	Bartnikas, Craig D. Platt, Toshiro K. Ohsumi [‡] , Janet Chou [‡]		
8			
9	*A. A. Nguyen, S. B. Habiballah, and B. LaBere contributed equally		
10	[‡] T. K. Ohsumi and J. Chou contributed equally		
11			
12	Affiliations: Division of Immunology, Boston Children's Hospital and Harvard Medical School, Boston,		
13	Massachusetts (A.A.N, S.B.H., B.L., M.D-L., M.E., A.A., A.C., J.J., A.J.F., D.M., D.H., H.C.O., L.C.S.,		
14	A.M., L.B., C.D.P., J.C); Research Computing, Information Technology, Boston Children's Hospital,		
15	Boston, MA (S.R., P.S.); The Manton Center for Orphan Disease Research, Boston Children's Hospital,		
16	Boston, Massachusetts (S.R., P.S.); Division of Molecular Medicine, Boston Children's Hospital, Boston,		
17	Massachusetts (P.S.); Be Biopharma, Boston, Massachusetts (T.K.O.)		
18	[†] Current affiliation: Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah,		
19	KSA (S.B.H)		
20			
21	Disclosures: No authors have disclosures relevant to the content of this manuscript.		
22	Corresponding author: Janet Chou, MD, Boston Children's Hospital, 300 Longwood Avenue, Boston,		
23	MA 02115; email: Janet.Chou@childrens.harvard.edu		
24			

25 Abstract

Background. Debates on the allocation of medical resources during the COVID-19 pandemic revealed the need for a better understanding of immunologic risk. Studies highlighted variable clinical outcomes of SARS-CoV-2 infections in individuals with defects in both adaptive and innate immunity, suggesting additional contributions from other factors. Notably, none of these studies controlled for variables linked with social determinants of health.

31 **Objective**. To determine the contributions of determinants of health to risk of hospitalization for SARS-

32 CoV-2 infection among individuals with inborn errors of immunodeficiencies.

33 Methods. This is a retrospective, single-center cohort study of 166 individuals with inborn errors of
 34 immunity, aged two months through 69 years, who developed SARS-CoV-2 infections from March 1,
 35 2020 through March 31, 2022. Risks of hospitalization was assessed using a multivariable logistic
 36 regression analysis.

37 **Results.** The risk of SARS-CoV-2-related hospitalization was associated with underrepresented racial and 38 ethnic populations (odds ratio [OR] 5.29; confidence interval [CI], 1.76-17.0), a diagnosis of any 39 genetically-defined immunodeficiency (OR 4.62; CI, 1.60-14.8), use of B cell depleting therapy within 40 one year of infection (OR 6.1; CI, 1.05-38.5), obesity (OR 3.74; CI, 1.17-12.5), and neurologic disease 41 (OR 5.38; CI, 1.61-17.8). COVID-19 vaccination was associated with reduced hospitalization risk (OR 42 0.52; CI, 0.31-0.81). Defective T cell function, immune-mediated organ dysfunction, and social 43 vulnerability were not associated with increased risk of hospitalization after controlling for covariates. 44 **Conclusions.** The associations between race, ethnicity, and obesity with increased risk of hospitalization 45 for SARS-CoV-2 infection indicate the importance of variables linked with social determinants of health

46 as immunologic risk factors for individuals with inborn errors of immunity.

47

48 Highlights:

49	1.	What is already known about this topic? Outcomes of SARS-CoV-2 infections in individuals		
50		with inborn errors of immunity (IEI) are highly variable. Prior studies of patients with IEI have		
51		not controlled for race or social vulnerability.		
52	2.	What does this article add to our knowledge? For individuals with IEI, hospitalizations for		
53		SARS-CoV-2 were associated with race, ethnicity, obesity, and neurologic disease. Specific types		
54		of immunodeficiency, organ dysfunction, and social vulnerability were not associated with		
55	increased risk of hospitalization.			
56	3.	How does this study impact current management guidelines? Current guidelines for the		
57		management of IEIs focus on risk conferred by genetic and cellular mechanisms. This study		
58		highlights the importance of considering variables linked with social determinants of health and		
59	common comorbidities as immunologic risk factors.			
60				
61	Key Words: SARS-CoV-2, COVID-19, health disparities, primary immunodeficiency, inborn errors of			
62	immunity			
63	Abbreviations: CI, confidence interval; COVID-19, Coronavirus disease 2019; IEI, inborn errors of			
64	immunity; OR, odds ratio; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; SDOH, social			
65	determinants of health; SVI: social vulnerability index.			

66

67

68

69 Introduction

70 The COVID-19 pandemic prompted dilemmas and debates regarding the allocation of medical 71 resources.^{1–3} These debates highlighted a critical gap in medicine that remains today: the paucity of 72 established measures of immunologic risk. This contrasts with the extensive framework of risk 73 assessment that is the bedrock of preventative medicine. The United States Department of Health and 74 Human Services Healthy People 2030 screening recommendations include assessments for cardiovascular 75 disease, osteoporosis, cancer, sexually transmitted diseases, mental health, diabetes, child development, pregnancy, and sensory or communication disorders⁴. While these recommendations were developed pre-76 77 pandemic, COVID-19 has heightened the importance of screening for immunologic risk which is notably 78 absent.

79 Current knowledge of immunologic risk is largely derived from clinical outcomes of primary or 80 secondary immunodeficiencies. Primary immunodeficiencies, commonly referred to as inborn errors of 81 immunity, consist of 485 disorders caused by defects in genes important for host immunity.⁵ Studies have 82 identified cellular and molecular mechanisms of susceptibility to SARS-CoV-2 among the four main 83 types of inborn errors of immunity: (1) combined immunodeficiencies with diminished T and B cell 84 function, (2) humoral immunodeficiencies impairing B cell function, (3) defective innate immunity 85 affecting innate immune cells or signaling, and (4) primary immune regulatory disorders with autoimmunity as the dominant feature (Figure 1A).^{6,7} In the U.S., national guidelines for prioritizing anti-86 87 SARS-CoV-2 therapies highlighted defective T cell function as a high risk condition due to the established role of T cells in orchestrating serologic immunity and eradicating virus-infected cells.⁸ 88 89 Surprisingly, patients with severe combined immunodeficiency exhibited a spectrum of outcomes with 90 SARS-CoV-2 infections, ranging from mild to fatal In addition to highlighting the important of innate 91 immunity, multiple studies revealed conflicting outcomes of SARS-CoV-2 infections in individuals with other types of inborn errors of immunity,^{6,9–22} suggesting additional risk factors beyond mechanistically-92 93 defined immune defects. As these studies were predominantly comprised of adults and few included 94 multivariate analyses, the relative contributions of age, comorbidities, and immunologic defects were not

delineated. None of these studies controlled for race, Hispanic ethnicity, or social vulnerability. Thus, the
relative contributions of molecular risk factors compared to socioeconomic disparities to SARS-CoV-2
infection outcomes remain unknown.

We hypothesized that general risk factors and variables associated with health disparities such as race and ethnicity correlate with increased immunologic risk, even in a population with mechanistically defined immunodeficiencies. We performed a two-year retrospective cohort study of 166 patients with inborn errors of immunity, aged two months through 69 years of age. Of published studies to date, this is the largest and longest study of outcomes from SARS-CoV-2 infections in patients with inborn errors of immunity.

104

105 Methods

106 *Study design and setting.* This is a retrospective, single-center cohort study at Boston Children's 107 Hospital. As one of the nation's largest clinical immunology programs, the Division of Immunology 108 provides longitudinal outpatient care for patients with inborn errors of immunity ranging from the 109 neonatal period through 75 years of age and inpatient care for individuals until the age of 35 years. 110 Hospitalization for those older than 35 years is coordinated at adult hospitals. Patients in our cohort had a 111 median follow-up of 9.1 years in our immunology clinic. This study was approved by the Boston 112 Children's Hospital Institutional Review Board.

113 Study objectives, variables, and outcome. We aimed to determine factors associated with severe 114 SARS-CoV-2 infections in patients with inborn errors of immunity, with hospitalizations as the primary 115 outcome. Data were abstracted from the Boston Children's Hospital electronic medical record by clinical 116 immunologists using a standardized data collection instrument. To reduce bias inherent in a retrospective 117 study, variables were defined prior to study initiation: age, race, ethnicity, social vulnerability index 118 (SVI), past medical history, and history of vaccinations and therapeutics against SARS-CoV-2. Race and 119 ethnicity were classified based on patient self-report in the electronic medical record. Patient zip codes were matched to census tracts for determination of SVI.²³ For zip codes contained within multiple census 120

121 tracts, a weighted average SVI was calculated using the American Community Survey 2014-2018 population estimates.²⁴ Defective T cell function was defined as 30% of normal PHA proliferation and/or 122 123 history of opportunistic infections indicative of impaired T cell function 25 . We identified patients with 124 organ dysfunction, as defined by: (1) histological evidence of immune cell infiltration in organs, or (2) 125 laboratory or otherwise measurable evidence of impaired organ function attributed by the patient's 126 primary immunologist to recurrent infections, autoimmunity, or chronic inflammation. Organ dysfunction 127 criteria were met prior to COVID-19 infections. Obesity was defined based on CDC definitions of weight 128 classification: in patients under 20 years of age, BMI at the 95th percentile or higher was used; in patients 129 over 20 years of age, BMI of 30 or greater was used. Reasons for hospitalization were determined by 130 chart review, as specified by the admission note. Respiratory insufficiency was defined as increased work 131 of breathing, hypoxia, or respiratory failure. Hemodynamic instability was defined as unstable or low 132 blood pressure requiring intervention. Worsening immune dysregulation was defined as evidence of 133 active disease-specific organ dysfunction or cytopenias. Fever and neutropenia were defined as 134 temperatures >38C and absolute neutrophil count <500 cells/microliter. Severe gastrointestinal symptoms 135 included vomiting and/or diarrhea causing electrolyte derangements and/or hypotension requiring 136 intervention. Clinical monitoring due to clinician concern was dependent on physician concern related to 137 the patient's baseline health status, diagnosis, and perceived risk in the setting of acute SARS CoV-2.

138 Patients. Patients eligible for this study had (1) a diagnosis of an inborn error of immunity and (2) 139 positive nucleic acid amplification test or antigen test for SARS-CoV-2 infection between March 15, 140 2020 through March 31, 2022 (Figure 1B). Specifically, patients with inborn errors of immunity were 141 first identified by an ICD-10 code (Figure E2) used for a clinical visit between January 1, 2015 and 142 January 1, 2020, which was verified through a medical record review by this study's clinical immunology 143 team. Patients with positive testing for SARS-CoV-2 were identified through review of: (1) SARS-CoV-2 144 testing results available at Boston Children's Hospital, (2) referrals for SARS-CoV-2 therapeutics, (3) and 145 medical records. Patients were not eligible if they had a secondary or acquired immunodeficiency. There

were no inpatients incidentally found to have positive SARS-CoV-2 RT-PCR while hospitalized fordiagnoses unrelated to COVID-19.

148 Statistical analyses. We used a multivariable logistic analysis to identify potential risk factors for 149 hospitalization due to SARS-CoV-2. Variance inflation factors were used to assess multicollinearity of 150 potential covariates²⁶. Since hospitalization for acute SARS-CoV-2 infections are relatively rare until the 151 sixth decade of life²⁷, we performed the logistic regression with penalized likelihood to reduce the bias 152 inherent in small sample sizes²⁸. As a confirmatory approach, we also identified risk factors for 153 hospitalization using a standard logistic regression model with the same variables. There was no missing 154 data in this data set. Statistical analyses were performed with Statistical Package for the Social Science 155 (SPSS, version 27.0 software) and R Statistical Software (version 4.1.3).

Role of the funding source. The funding source had no role in the design, execution, analysis, orreporting of this study.

158

159 **Results**

160 Patient Characteristics

161 Among 2513 patients with a confirmed diagnosis of an inborn error of immunity, 166 had at least 162 one SARS-CoV-2 infection during the study period (Figure 1B). Thirty-one patients were hospitalized 163 (Table 1), most commonly for respiratory failure (Table 2). Twelve patients required critical care and 164 one died. The median age of inpatients was 16.3 years (range 0.5 - 51.7 years), compared with 14.9 years 165 for outpatients (range 0.2 - 68.8 years). The percentage of hospitalized patients (18.7%, with a median 166 age of 16.3 years) is higher than that of the general pediatric and adolescent population, which has been estimated to be less than 5%.^{29,30} Hospitalized patients were more likely to be male, of Black, 167 168 Asian/Pacific Islander, American Indian, or Alaskan Native racial backgrounds, of Hispanic ethnicity, and 169 living in an area with a higher social vulnerability index (Table 1). Of the 36 individuals who were of 170 Black, Asian/Pacific Islander, American Indian, or Alaskan Native racial backgrounds or Hispanic

ethnicity, 42.4% were hospitalized. Sixty-four patients (38%) had COVID-19 in the period after
December 31, 2021 when Omicron accounted for the majority of infections in Massachusetts.

173 Humoral immunodeficiencies were the most common type of inborn error of immunity, followed 174 by combined immunodeficiencies (Table 1). Among inpatients, 64.5% had a genetically defined immune 175 disorder attributable to a genetic variant confirmed by clinical-grade DNA sequencing, compared to 176 34.1% of outpatients (Table 1). Organ dysfunction caused by recurrent infections and/or autoimmunity is 177 a complication of inborn errors of immunity that may be treated with B cell-depleting therapies.³¹ 178 Inpatients were more likely to have organ dysfunction and B cell depleting therapies within one year prior 179 to infection, compared to outpatients. Among comorbidities known to be associated with severe COVID-19.32 obesity, neurologic disease, chronic renal disease, and cardiovascular disease were the most 180 181 common and occurred more frequently in inpatients than outpatients (**Table 1**).

182

183 Use of COVID-19 medical interventions

FDA emergency authorization for COVID-19 vaccines was granted in December 2020, but distribution was hampered by limitations in supply, logistics, and public trust.³³ The majority of inpatients (74.2%) and outpatients (57.0%) were infected with SARS-CoV-2 before COVID-19 vaccination. Additionally, 35 patients received post-exposure treatment with monoclonal antibodies SARS-CoV-2 as they were asymptomatic but tested positive, in accordance with FDA recommendations, three of whom required subsequent hospitalization due to worsening disease.

190

191 Risk factors associated with hospitalization among patients with inborn errors of immunity

Among demographic factors, Black, Asian/Pacific Islander, American Indian, or Alaskan Native racial background and/or Hispanic ethnicity was significantly associated with an increased risk of hospitalization (OR 5.29; CI, 1.75-17.0), while social vulnerability index was not. Older age was associated with a marginally increased risk of hospitalization (OR 1.05; CI, 1.01-1.10). Hospitalization was also associated with the following clinical features relevant to inborn errors of immunity: a history of

197 a genetically defined immunodeficiency (OR 4.62; CI, 1.60-14.8) and treatment with B cell depleting 198 agents within one year of infection (OR 6.10; CI, 1.05-38.5). Notably, neither defective T cell function 199 nor a history of immune-associated organ dysfunction was associated with an increased risk of 200 hospitalization. Among the comorbidities associated with severe COVID-19 in the general population, 201 obesity (OR 3.74; CI, 1.17 to 12.5) and a history of neurologic disease (OR 5.38; CI, 1.61 to 17.8), were 202 associated with increased risk of hospitalization. Infection after December 31, 2021, at which point the 203 Omicron variant accounted for over 95% of SARS-CoV-2 infections in Massachusetts, was not associated 204 with increased hospitalizations. With respect to SARS-CoV-2 interventions, an increased number of 205 COVID-19 vaccination doses was associated with reduced hospitalization risk (OR 0.52; CI, 0.31-0.81), 206 while treatment with SARS-CoV-2 monoclonal antibody was not statistically significant. A standard 207 logistic regression model identified the same risk factors with similar adjusted ORs (Figure 2 and Figure 208 E1).

209

210 Discussion

Although inborn errors of immunity are rare diseases, they serve as real-world disease models that enable delineation of specific pathways contributing to immunologic risk. While rare disease research focuses on disease-specific principles toward a goal of personalized medicine, common risk factors for disease can be overlooked. Prior studies have not assessed the contributions of race, ethnicity, or social vulnerability to outcomes from SARS-CoV-2 infection in individuals with inborn errors of immunity.^{6,9–21} Our study reveals the importance of contextualizing host immunity within common determinants of health, which are significant contributors to outcomes from SARS-CoV-2 infections.

We found that obesity was associated with increased odds of hospitalization, concordant with SARS-CoV-2 outcomes in the general pediatric and adult populations.^{34,35} Guidelines for clinical management of inborn errors of immunity highlight low body weight as a predictor of immunologic compromise.^{21,25} However, the prevalence of obesity in pediatric and adult patients with inborn errors of immunity is now comparable to that of the general population.³⁶ During the H1N1 influenza pandemic,

223 obesity was also associated with increased morbidity and mortality in the general population.³⁷ Adipose 224 tissue can serve as a reservoir for viral replication, the priming of inflammatory myeloid and lymphoid 225 cells, and a source of inflammatory cytokines and adipokines.³⁸ Future studies are needed to determine 226 how obesity influences clinical outcomes other than SARS-CoV-2 infections in patients with inborn 227 errors of immunity.

228 Here, we show that underrepresented racial and ethnic groups, but not SVI, are associated with 229 increased odds of hospitalization. The lack of association between SVI and SARS-CoV-2-related 230 hospitalizations in our study may arise from the availability of medical coverage for children and 231 adolescents living in Massachusetts, which is the highest in the U.S.: only 1.2% of children in Massachusetts are uninsured, compared to a national average of 5.2%.³⁹ Approximately one third of 232 233 children in Massachusetts receive healthcare through the state's Medicaid program providing school-234 based medical care.³⁹ Additionally, this study was conducted at a tertiary medical center providing 235 immunology subspecialty care. However, the persistent disparities in healthcare are underscored by the 236 5.2-fold odds of hospitalization associated with Black, Black, Asian/Pacific Islander, American Indian, or 237 Alaskan Native race and/or Hispanic ethnicity in this study. This is concordant with studies in the general 238 pediatric population showing increased hospitalizations and deaths from SARS-CoV-2 infections among 239 non-Hispanic Black or Hispanic children compared to White children.^{40,41}

240 Race and ethnicity have inextricably been linked with disadvantages in SDOH for minority groups when pertaining to specific conditions, including cardiovascular disease⁴² and diabetes.⁴³ With 241 242 regards to COVID-19, on a county level in the US there is association between adverse SDOH factors, 243 percent Black residents, and mortality rate. However, in counties with below average adverse SDOH 244 factors there was no association between percent Black residents and mortality, implying that racial disparities are driven by social constructs.⁴⁴ Specific to the pediatric population, there are significant 245 246 racial and ethnic differences across all categories of SDOH, including economic stability, education 247 access and quality, health care access and quality, neighborhood and built environment, and social and 248 community context.⁴⁵ Interestingly, within our cohort race and ethnicity were associated with

hospitalizations independent of SVI, indicating that additional studies are needed to delineate how underlying inequities and structural racism affect other outcomes in patients with inborn errors of immunity.

252 Our findings identify a potential role for genetic sequencing in assessing immunologic risk. The 253 heterogenous clinical phenotypes of inborn errors of immunity complicate the diagnosis and management 254 of these disorders. Defining the underlying genetic etiology improves understanding of patient 255 phenotypes can guide directed therapies.¹ Despite the declining costs of genetic sequencing, genetic tests are not routinely covered by most insurance companie.⁴⁶ Genetic diagnoses in our cohort were made 256 257 feasible by an institutional program that enables clinical whole exome sequencing at no cost to patients.⁴⁷ 258 In our study, patients with a genetically defined immunodeficiency had 5.3-fold greater odds of 259 hospitalization. Within this group, there was no significant predilection among types of genetic defects: 260 there were similar numbers of hospitalized patients with combined defects and humoral defects, with 261 fewer patients with innate defects or PIRD (Figure E2). The reasons for hospitalization indicate that our 262 findings were not attributable to clinical monitoring of patients with genetic diagnoses (Table 2). Rather, 263 we posit that individuals with genetically confirmed immunodeficiencies have more severe immunologic 264 disease and thus, a higher risk of severe SARS-CoV-2 infections. This hypothesis is supported by 265 evidence showing that the likelihood of a genetic diagnosis is higher in patients with severe clinical 266 presentations.²¹ Disease severity was controlled in our analysis using organ dysfunction as a surrogate. 267 Notably, organ dysfunction – a standard measure of disease severity for disorders of immunity³¹ – was not 268 associated with increased hospitalization risk in our cohort, even though it was present in 45.2% of 269 inpatients and 34.1% of outpatients. Thus, genetic diagnoses may enable better identification of 270 individuals with increased immunologic risk. Identification of genetic disorders will be made possible 271 only through equitable access to genetic testing, a goal that remains elusive in the U.S. due to gaps in 272 clinician knowledge, limited and inconsistent insurance coverage of genetic tests, and the scarcity of 273 community-based or patient-centered educational resources in genomic medicine.⁴⁸

274 Although hospitalization was most frequent in those with innate immune defects or combined 275 immunodeficiencies, we did not find a significant association of defective T cell immunity with 276 hospitalization when controlling for covariates. This may be due, at least in part, to national newborn screening programs for severe combined immunodeficiency that enable early diagnosis and treatment.⁴⁹ 277 278 Thus, most children with the most severe combined immunodeficiencies will have undergone 279 hematopoietic stem cell transplantation before entry into daycare and school settings with potentially high 280 levels of viral transmission. We found that increasing numbers of COVID-19 vaccinations were 281 associated with a significantly reduced risk of hospitalization, further providing evidence that the school-282 aged and older individuals in this cohort had partial retention of immune function. Similarly, the largest 283 study of mRNA vaccine efficacy in individuals with congenital immunodeficiencies found that the 284 majority of patients with combined immunodeficiencies mounted an intact vaccine-specific T cell 285 response.⁵⁰ Although impaired T cell function is a commonly used measure of susceptibility to viral 286 infections, our study highlights the limitations of applying this principle without acknowledgement of 287 other determinants for health. Genetic diagnoses, obesity, comorbid conditions, and race modulate the 288 immunologic risk often attributed solely to the mechanisms underlying congenital immunodeficiencies.

By using a multivariate regression model, we adjusted for variations in SARS-CoV-2 directed interventions as some patients received vaccines and monoclonal antibodies while others did not. These differences were largely due to the availability of these agents during time of infection and governmental recommendations regarding eligibility. Similar models have been used to account for confounding factors in COVID-19 studies.^{51,52} Furthermore, the single center design of our study minimized variability in clinical practice. Patients with primary immunodeficiencies and SARS-CoV-2 infection were managed using institution-approved guidelines and algorithms to standardize modalities of care.

Our study has limitations. This is a single center, retrospective study and inborn errors of immunity are rare diseases. It is infeasible to definitively determine the total number of patients with SARS-CoV-2 infections because SARS-CoV-2 test availability was limited at the start of the pandemic, patients may not report all positive home antigen tests to healthcare providers, and asymptomatic SARS-

300	CoV-2 infections are underreported. Given the limitations inherent in studies of rare diseases with small
301	sample sizes, our study sought to determine the contributions of common risk factors that are often
302	overlooked in rare diseases due to the "N of 1" approach typical of personalized medicine.
303	The morbidity and mortality caused by the COVID-19 pandemic transformed immunologic risk
304	from an abstract concept into a real-world axis that influences daily decisions about school, work, and
305	travel. The findings of this study indicate the importance of considering factors beyond molecular
306	mechanisms as measures of immunologic risk and suggest that this risk can be modified by initiatives
307	pertaining to obesity and healthcare disparities.

308

309 Acknowledgements

- 310 This study was supported by the National Institutes of Health (T32AI007512 to H.C.O., A.A.N.,
- 311 B.L., D.H.; K23AI143962 to L.M.B., R01DK130465 and R01AI139633-04S1 to J.C.), the Wallace
- 312 Family Fund and Perkins Fund (to J.C.), and the Department of Pediatrics at King Abdulaziz University,
- 313 Jeddah, KSA (to S.B.H.).
- 314
- 315

316 **References**

- Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, et al. Fair Allocation of Scarce
 Medical Resources in the Time of Covid-19. N Engl J Med. 2020;382(21):2049–55.
- Lemmon ME, Truog RD, Ubel PA. Allocating Resources Across the Life Span During COVID-19—
 Integrating Neonates and Children Into Crisis Standards of Care Protocols. JAMA Pediatrics.
 2021;175(4):347–8.
- Bledsoe TA, Jokela JA, Deep NN, Snyder Sulmasy L. Universal Do-Not-Resuscitate Orders, Social
 Worth, and Life-Years: Opposing Discriminatory Approaches to the Allocation of Resources
 During the COVID-19 Pandemic and Other Health System Catastrophes. Ann Intern Med.
 2020;M20-1862.
- 326 4. Healthy People 2030 | health.gov.
- Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human
 Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of
 Immunological Societies Expert Committee. J Clin Immunol. 2022;42(7):1473–507.
- Bucciol G, Tangye SG, Meyts I. Coronavirus disease 2019 in patients with inborn errors of
 immunity: lessons learned. Curr Opin Pediatr. 2021;33(6):648–56.
- Zhang Q, Bastard P, COVID Human Genetic Effort, Cobat A, Casanova J-L. Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature. 2022;603(7902):587–98.
- 8. Prioritization of Therapeutics. COVID-19 Treatment Guidelines.
- Meyts I, Bucciol G, Quinti I, Neven B, Fischer A, Seoane E, et al. Coronavirus disease 2019 in
 patients with inborn errors of immunity: An international study. J Allergy Clin Immunol.
 2021;147(2):520–31.
- Karakoc Aydiner E, Bilgic Eltan S, Babayeva R, Aydiner O, Kepenekli E, Kolukisa B, et al. Adverse
 COVID-19 outcomes in immune deficiencies: Inequality exists between subclasses. Allergy.
 2022;77(1):282–95.

- 341 11. Castano-Jaramillo LM, Yamazaki-Nakashimada MA, O'Farrill-Romanillos PM, Muzquiz Zermeño 342 D, Scheffler Mendoza SC, Venegas Montoya E, et al. COVID-19 in the Context of Inborn Errors of 343 Immunity: a Case Series of 31 Patients from Mexico. J Clin Immunol. 2021;41(7):1463–78. 344 12. Esenboga S, Ocak M, Akarsu A, Bildik HN, Cagdas D, Iskit AT, et al. COVID-19 in Patients with 345 Primary Immunodeficiency. J Clin Immunol. 2021;41(7):1515-22. 346 13. Goudouris ES, Pinto-Mariz F, Mendonça LO, Aranda CS, Guimarães RR, Kokron C, et al. Outcome 347 of SARS-CoV-2 Infection in 121 Patients with Inborn Errors of Immunity: A Cross-Sectional 348 Study. J Clin Immunol. 2021;41(7):1479–89. 349 14. Ho H, Mathew S, Peluso MJ, Cunningham-Rundles C. Clinical outcomes and features of COVID-19 350 in patients with primary immunodeficiencies in New York City. J Allergy Clin Immunol Pract. 351 2021;9(1):490-493.e2. 352 15. Marcus N, Frizinsky S, Hagin D, Ovadia A, Hanna S, Farkash M, et al. Minor Clinical Impact of 353 COVID-19 Pandemic on Patients With Primary Immunodeficiency in Israel. Front Immunol. 354 2020;11:614086. 355 16. Milito C, Lougaris V, Giardino G, Punziano A, Vultaggio A, Carrabba M, et al. Clinical outcome, 356 incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of 357 immunity. J Allergy Clin Immunol Pract. 2021;9(7):2904-2906.e2. 358 17. Milota T, Sobotkova M, Smetanova J, Bloomfield M, Vydlakova J, Chovancova Z, et al. Risk 359 Factors for Severe COVID-19 and Hospital Admission in Patients With Inborn Errors of Immunity -360 Results From a Multicenter Nationwide Study. Front Immunol. 2022;13:835770. 361 18. Moazzen N, Ahanchian H, Aelami MH, Asiyon H, Astaneh M, Naeimi AM, et al. COVID-19 in 362 children with inborn errors of immunity: clinical scenarios. Am J Clin Exp Immunol. 363 2021;10(3):77-85. 364 19. Shields AM, Burns SO, Savic S, Richter AG, UK PIN COVID-19 Consortium. COVID-19 in patients 365 with primary and secondary immunodeficiency: The United Kingdom experience. J Allergy Clin 366 Immunol. 2021;147(3):870-875.e1. 367 20. The Impact of SARS-CoV-2 Infection in Patients with Inborn Errors of Immunity: the Experience of 368 the Italian Primary Immunodeficiencies Network (IPINet) - PubMed. 369 21. Abolhassani H, Delavari S, Landegren N, Shokri S, Bastard P, Du L, et al. Genetic and immunologic 370 evaluation of children with inborn errors of immunity and severe or critical COVID-19. J Allergy 371 Clin Immunol. 2022;150(5):1059-73. 372 22. Cousins K, DeFelice N, Jeong S, Feng J, Lee ASE, Rotella K, et al. SARS-COV-2 infections in 373 inborn errors of immunity: A single center study. Frontiers in Immunology. 2022;13. 374 23. CDC/ATSDR Social Vulnerability Index (SVI). 2022.
- 375 24. Bureau UC. American Community Survey 2014-2018 5-Year Estimates Now Available. Census.gov.

- 376 25. Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al. Practice parameter for the
 377 diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol.
 378 2015;136(5):1186-1205.e1-78.
- 26. Vatcheva KP, Lee M, McCormick JB, Rahbar MH. Multicollinearity in Regression Analyses
 Conducted in Epidemiologic Studies. Epidemiology (Sunnyvale). 2016;6(2):227.
- 381 27. Cases, Data, and Surveillance. Centers for Disease Control and Prevention. 2020.
- 382 28. Firth D. Bias Reduction of Maximum Likelihood Estimates. Biometrika. 1993;80(1):27–38.
- 383 29. Molteni E, Sudre CH, Canas LS, Bhopal SS, Hughes RC, Antonelli M, et al. Illness duration and
 384 symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. The Lancet
 385 Child & Adolescent Health. 2021;5(10):708–18.
- 386 30. Forrest CB, Burrows EK, Mejias A, Razzaghi H, Christakis D, Jhaveri R, et al. Severity of Acute
 387 COVID-19 in Children <18 Years Old March 2020 to December 2021. Pediatrics.
 388 2022;149(4):e2021055765.
- 389 31. Delmonte OM, Castagnoli R, Calzoni E, Notarangelo LD. Inborn Errors of Immunity With Immune
 390 Dysregulation: From Bench to Bedside. Front Pediatr. 2019;7:353.
- 391 32. People with Certain Medical Conditions. Centers for Disease Control and Prevention. 2023.
- 392 33. Jean-Jacques M, Bauchner H. Vaccine Distribution—Equity Left Behind? JAMA. 2021;325(9):829–
 30.
- 394 34. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated
 395 with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–6.

396 35. Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, et al. Characteristics
397 and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in
398 Children (MIS-C) Compared With Severe Acute COVID-19. JAMA. 2021;325(11):1074–87.

- 399 36. Ruffner MA, Sullivan KE. Complications associated with underweight primary immunodeficiency
 400 patients: prevalence and associations within the USIDNET Registry. J Clin Immunol.
 401 2018;38(3):283–93.
- 402 37. Van Kerkhove MD, Vandemaele KAH, Shinde V, Jaramillo-Gutierrez G, Koukounari A, Donnelly
 403 CA, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global
 404 pooled analysis. PLoS Med. 2011;8(7):e1001053.
- 405 38. Kanneganti T-D, Dixit VD. Immunological complications of obesity. Nat Immunol. 2012;13(8):707–
 406 12.
- 407 39. The Number of Uninsured Children is on the Rise. Center For Children and Families. 2019.
- 408 40. Moreira A, Chorath K, Rajasekaran K, Burmeister F, Ahmed M, Moreira A. Demographic predictors
 409 of hospitalization and mortality in US children with COVID-19. Eur J Pediatr. 2021;180(5):1659–
 410 63.

- 411 41. Antoon JW, Grijalva CG, Thurm C, Richardson T, Spaulding AB, Teufel RJ, et al. Factors
 412 Associated With COVID-19 Disease Severity in US Children and Adolescents. J Hosp Med.
 413 2021;16(10):603–10.
- 414 42. Javed Z, Haisum Maqsood M, Yahya T, Amin Z, Acquah I, Valero-Elizondo J, et al. Race, Racism,
 415 and Cardiovascular Health: Applying a Social Determinants of Health Framework to Racial/Ethnic
 416 Disparities in Cardiovascular Disease. Circ Cardiovasc Qual Outcomes. 2022;15(1):e007917.
- 417 43. Walker RJ, Strom Williams J, Egede LE. Influence of Race, Ethnicity and Social Determinants of
 418 Health on Diabetes Outcomes. Am J Med Sci. 2016;351(4):366–73.
- 419 44. Dalsania AK, Fastiggi MJ, Kahlam A, Shah R, Patel K, Shiau S, et al. The Relationship Between
 420 Social Determinants of Health and Racial Disparities in COVID-19 Mortality. J Racial Ethn Health
 421 Disparities. 2022;9(1):288–95.
- 422 45. Monroe P, Campbell JA, Harris M, Egede LE. Racial/ethnic differences in social determinants of
 423 health and health outcomes among adolescents and youth ages 10–24 years old: a scoping review.
 424 BMC Public Health. 2023;23(1):410.
- 46. Reuter CM, Kohler JN, Bonner D, Zastrow D, Fernandez L, Dries A, et al. Yield of whole exome
 sequencing in undiagnosed patients facing insurance coverage barriers to genetic testing. J Genet
 427 Couns. 2019;28(6):1107–18.
- 428 47. Rockowitz S, LeCompte N, Carmack M, Quitadamo A, Wang L, Park M, et al. Children's rare
 429 disease cohorts: an integrative research and clinical genomics initiative. npj Genom Med.
 430 2020;5(1):1–12.
- 431 48. National Academies of Sciences E, Division H and M, Policy B on HS, Health R on G and P.
 432 Introduction and Overview. In: Understanding Disparities in Access to Genomic Medicine:
 433 Proceedings of a Workshop. National Academies Press (US); 2018.
- 434 49. Lankester AC, Albert MH, Booth C, Gennery AR, Güngör T, Hönig M, et al. EBMT/ESID inborn
 435 errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of
 436 immunity. Bone Marrow Transplant. 2021;56(9):2052–62.
- 437 50. van Leeuwen LPM, GeurtsvanKessel CH, Ellerbroek PM, de Bree GJ, Potjewijd J, Rutgers A, et al.
 438 Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of
 439 immunity. J Allergy Clin Immunol. 2022;149(6):1949–57.
- 440 51. Adir Y, Humbert M, Saliba W. COVID-19 risk and outcomes in adult asthmatic patients treated with
 441 biologics or systemic corticosteroids: Nationwide real-world evidence. J Allergy Clin Immunol.
 442 2021;148(2):361-367.e13.
- 443 52. Guan W-J, Liang W-H, Shi Y, Gan L-X, Wang H-B, He J-X, et al. Chronic Respiratory Diseases and 444 the Outcomes of COVID-19: A Nationwide Retrospective Cohort Study of 39,420 Cases. J Allergy 445 Clin Immunol Pract. 2021;9(7):2645-2655.e14.

446

447

448

449

450 Figure Legends.

- 451 Figure 1. Summary of study design. (A) Affected pathways implicated in the four main categories of
- 452 inborn errors of immunity. (B) Flow diagram of study participants.

453 Figure 2. Adjusted risk of SARS-CoV-2-related hospitalization in individuals with inborn errors of

- 454 immunity. Odds ratios and 95% confidence intervals (CI) for each respective determinant of health, as
- 455 calculated by logistic regression with covariate analysis. After December 31, 2021, the Omicron variant
- 456 accounted for at least 95% of SARS-CoV-2 infections.
- 457 Figure E1. Secondary analysis of adjusted risk of SARS-CoV-2-related hospitalization in

458 individuals with inborn errors of immunity. Odds ratios and 95% confidence intervals (CI) derived

- 459 from a standard logistic regression analysis model, after adjusting for all covariates listed. After
- 460 December 31, 2021, the Omicron variant (the first SARS-CoV-2 variant to have immune escape)
- 461 accounted for at least 95% of SARS-CoV-2 infections.
- 462 Figure E2. Severity of SARS-CoV-2 infection in patients with genetically defined inborn errors of
- 463 immunity. Monogenic inborn errors of immunity separated by severity of disease and categorized by
- 464 phenotypic classification.

	Hospitalized n = 31	Outpatient n = 135
Median age, years (range)	$\frac{11 = 31}{16.3 (0.5 - 51.7)}$	$\frac{11 = 135}{14.9 (0.2 - 68.8)}$
Age subgroups, n (%)		
$\frac{0.2 - 5 \text{ years}}{0.2 - 5 \text{ years}}$	6 (19.4)	18 (13.3)
5-12 years	8 (25.8)	36 (26.7)
12-18 years	6 (19.4)	37 (27.4)
18 – 29 years	8 (25.8)	29 (21.5)
29 – 69 years	3 (9.6)	15 (11.1)
Biologic sex, n (%)		~ /
Male	18 (58.1)	73 (54.1)
Female	13 (41.9)	62 (45.9)
Self-reported race, n (%)		
Asian/Pacific Islander	2 (6.5)	2 (1.5)
Black	3 (9.7)	6 (4.4)
American Indian or Alaska Native	1 (3.2)	0
White	17 (54.8)	116 (86.0)
Other ^a	8 (25.8)	11 (8.1)
Self-reported ethnicity, <i>n</i> (%)	I	I
Hispanic	8 (25.8)	8 (5.9)
Non-Hispanic	23 (74.2)	127 (94.1)
Median Social vulnerability index (range)	0.41 (0.10 - 0.88)	0.28 (0.018 - 0.97)
Subtypes of inborn errors of immunity, <i>n</i> (%)		
Humoral immune defects	12 (37.5)	83 (61.5)
Combined immune deficiency	11 (35.5)	30 (22.2)
Innate immune defect	3 (9.7)	4 (3.0)
Primary immune dysregulatory disorder	5 (16.1)	18 (13.3)
Clinical features and comorbidities, <i>n</i> (%)		
Genetically-defined inborn error of immunity	20 (64.5)	46 (34.1)
End-organ dysfunction	14 (45.2)	46 (34.1)
Rituximab treatment at time of infection	5 (16.1)	6 (4.4)
Obesity	10 (32.3)	22 (16.3)
Neurologic disease	8 (25.8)	16 (11.9)
Chronic renal disease	4 (12.9)	3 (2.2)
Cardiovascular disease	4 (12.9)	13 (9.6)
History of organ or stem cell transplantation	2 (6.5)	7 (5.2)
Malignancy	1 (3.2)	2 (1.5)
Chronic liver disease	1 (3.2)	6 (4.4)
Trisomy 21	1 (3.2)	3 (2.2)
COVID-19-related therapeutics n (%)		
Number of COVID-19 vaccine doses ^b		
0	24 (77.4)	77 (57.0)
1	3 (9.7)	1 (0.7)
2	2 (6.5)	31 (23.0)
3	2 (6.5)	26 (19.3)
Monoclonal antibodies against SARS-CoV-2 ^c	4 (12.9)	30 23.0)

a. For self-reported race, "other" denotes those patients who selected "other" as their racial background

b. All COVID-19 vaccines were given prior to April 2022, which exluded the bivalent formulations

c. Monoclonal antibodies included sotrovimab, bamlanivimab, casirivimab, imdevimab, and tixagevimab/cilgavimab

Table 2. Reasons for hospitalization*.

Cause	Number (%)
Respiratory instability	13 (42)
Hemodynamic instability	3 (10)
Worsening immune dysregulation	4 (13)
Fever and neutropenia	2 (6)
Severe gastrointestinal symptoms	4 (13)
Multisystem Inflammatory Syndrome in Children	3 (10)
Clinical monitoring due to clinician concern	2 (6)

*See Methods for information about category designation

Figure 1.




Figure 2.

